Akari Therapeutics, Plc
AKTXHealthcare|Biotechnology|US
$7.37
-0.38 (-4.90%)
DCF Value
$8.35
Cash / Share
$4.29
Financials
Financial Snapshot
Market Cap
$16.9M
Enterprise Value
$9.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$31.0M
Cash & Investments
$7.7M
Net Cash
$7.0M
Free Cash Flow (TTM)
-$10.7M
Operating CF (TTM)
-$10.7M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$7.7M
Quarterly Burn
$2.7M
Monthly Burn
$894.8K
Est. Runway
~2.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $44.1M | $28.1M | $6.0M | $5.7M | $14.1M | $9.4M | $13.3M | $3.8M | $2.6M | $5.2M | $7.7M | |
| Operating Cash Flow | -$24.6M | -$31.6M | -$22.5M | -$12.9M | -$17.0M | -$18.8M | -$21.5M | -$16.4M | -$12.6M | -$10.6M | -$10.7M | |
| Free Cash Flow | -$24.7M | -$31.6M | -$22.5M | -$12.9M | -$17.0M | -$18.8M | -$21.5M | -$16.4M | -$12.6M | -$10.6M | -$10.7M | |
| Capital Expenditure | -$54.8K | -$36.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$3.68 | |
| Financing Cash Flow | $0.00 | $15.7M | $306.0K | $12.6M | $25.1M | $14.3M | $25.3M | $7.0M | $11.0M | $13.2M | $15.7M |
R&D Spending
R&D (TTM)
$4.9M
R&D Intensity
—
R&D Growth vs Prior
+73.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $17.3M | $23.3M | $15.6M | $16.6M | $12.2M | $9.1M | $9.6M | $8.0M | $7.0M | $2.8M | $4.9M | |
| SG&A | $9.9M | $11.7M | $10.9M | $8.2M | $9.2M | $8.1M | $13.5M | $11.4M | $9.7M | $9.3M | $8.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $39.8K | $42.4K | $35.8K | $19.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$39.8K | -$42.4K | -$35.8K | -$19.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $17.3M | $23.3M | $15.6M | $16.6M | $12.2M | $9.1M | $9.6M | $8.0M | $7.0M | $2.8M | $4.9M | |
| SG&A | $9.9M | $11.7M | $10.9M | $8.2M | $9.2M | $8.1M | $13.5M | $11.4M | $9.7M | $9.3M | $8.8M | |
| Operating Income | -$27.2M | -$35.0M | -$20.0M | -$24.9M | -$18.0M | -$17.2M | -$23.1M | -$16.8M | -$21.6M | -$17.3M | -$31.0M | |
| Interest Expense | $9.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$244.0K | $949.0K | $984.3K | |
| Pretax Income | -$18.1M | -$32.6M | -$23.5M | -$24.8M | -$17.1M | -$17.4M | -$17.7M | -$10.0M | -$19.8M | -$18.3M | -$32.8M | |
| Net Income | -$18.1M | -$27.9M | -$19.9M | -$16.8M | -$17.1M | -$17.4M | -$17.7M | -$10.0M | -$19.8M | -$17.3M | -$31.0M | |
| EPS (Diluted) | -3200000.00 | -4800000.00 | -2129600.00 | -1472000.00 | -896000.00 | -649600.00 | -455200.00 | -163200.00 | -132800.00 | -20800.00 | -1600.00 | |
| EBITDA | -$27.2M | -$35.4M | -$16.4M | -$24.7M | -$18.0M | -$17.4M | -$17.7M | -$10.0M | -$19.5M | -$17.4M | -$31.8M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 1.79 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.1M | $28.1M | $6.0M | $5.7M | $14.1M | $9.4M | $13.3M | $3.8M | $2.6M | $5.2M | $7.7M | |
| Short-Term Investments | $10.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $45.6M | $28.8M | $16.4M | $10.3M | $14.6M | $11.6M | $13.8M | $4.3M | $3.0M | $5.5M | $8.3M | |
| Total Assets | $45.9M | $29.1M | $16.5M | $10.3M | $14.6M | $11.6M | $13.8M | $4.4M | $50.6M | $47.9M | $38.6M | |
| Total Current Liabilities | $11.7M | $9.0M | $3.1M | $5.5M | $5.2M | $6.1M | $12.0M | $4.6M | $19.9M | $12.4M | $13.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $11.8M | $9.1M | $3.1M | $6.5M | $5.2M | $6.1M | $12.0M | $4.6M | $28.3M | $19.6M | $20.0M | |
| Stockholders' Equity | $34.1M | $20.0M | $13.4M | $3.8M | $9.4M | $5.6M | $1.8M | -$229.0K | $22.2M | $28.3M | $18.6M | |
| Retained Earnings | -$74.9M | -$107.5M | -$116.5M | -$138.2M | -$182.3M | -$199.7M | -$217.5M | -$227.5M | -$247.3M | -$264.6M | -$283.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24.6M | -$31.6M | -$22.5M | -$12.9M | -$17.0M | -$18.8M | -$21.5M | -$16.4M | -$12.6M | -$10.6M | -$10.7M | |
| Capital Expenditure | -$54.8K | -$36.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$3.68 | |
| Free Cash Flow | -$24.7M | -$31.6M | -$22.5M | -$12.9M | -$17.0M | -$18.8M | -$21.5M | -$16.4M | -$12.6M | -$10.6M | -$10.7M | |
| Investing Cash Flow | -$10.1M | $10.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $382.0K | $0.00 | -$15.0K | |
| Financing Cash Flow | $0.00 | $15.7M | $306.0K | $12.6M | $25.1M | $14.3M | $25.3M | $7.0M | $11.0M | $13.2M | $15.7M | |
| Issuance of Stock | $0.00 | $15.7M | $500.0K | $12.6M | $25.0M | $14.3M | $25.2M | $7.0M | $11.8M | $12.1M | $14.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$855.0K | $1.0M | $1.4M | |
| Stock Based Comp. | $3.9M | $2.7M | $1.6M | $1.0M | $325.5K | $314.6K | $735.0K | $1.1M | $2.2M | $2.9M | $2.2M | |
| Net Change in Cash | -$34.8M | -$6.0M | -$22.3M | -$236.3K | $8.3M | -$4.7M | $3.9M | -$9.4M | -$1.2M | $2.6M | $5.0M |
Dilution Tracker
Shares outstanding grew 2566.7% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+2566.7%
Stock Issuance (TTM)
$14.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 1.79 | |
| Change vs Prior % | — | 5.8% | 23.8% | 18.7% | 72.6% | 36.0% | 45.4% | 56.9% | 144.1% | 252.3% | 8414.6% | |
| Stock Issuance | $0.00 | $15.7M | $500.0K | $12.6M | $25.0M | $14.3M | $25.2M | $7.0M | $11.8M | $12.1M | $14.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.9M | $2.7M | $1.6M | $1.0M | $325.5K | $314.6K | $735.0K | $1.1M | $2.2M | $2.9M | $2.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -53.2% | -139.8% | -149.1% | -439.2% | -182.0% | -313.7% | -991.0% | 4370.3% | -89.0% | -61.1% | -147.4% | |
| ROA % | -39.5% | -96.1% | -121.3% | -163.4% | -117.0% | -149.6% | -128.3% | -229.8% | -39.1% | -36.1% | -80.2% | |
| ROIC % | -79.6% | -149.6% | -126.9% | -348.9% | -191.6% | -309.9% | -1289.1% | 7338.9% | -63.8% | -45.0% | -115.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -291.5% | -6.6% | 15.5% | 46.4% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 10.9% | -28.3% | 42.8% | -24.4% | 27.7% | 4.3% | -34.1% | 27.2% | -28.8% | 20.2% | |
| Net Income | 60.0% | -53.9% | 28.6% | 15.6% | -1.4% | -2.0% | -1.9% | 43.6% | -97.8% | 12.6% | |
| EPS (Diluted) | 62.4% | -50.0% | 55.6% | 30.9% | 39.1% | 27.5% | 29.9% | 64.1% | 18.6% | 84.3% | |
| Operating Cash Flow | -395.9% | -28.3% | 28.7% | 42.7% | -31.2% | -11.2% | -14.1% | 23.6% | 23.6% | 15.8% | |
| Free Cash Flow | -396.0% | -28.2% | 28.8% | 42.7% | -31.2% | -11.2% | -14.1% | 23.6% | 23.6% | 15.8% | |
| R&D Expense | 198.4% | 34.6% | -33.1% | 6.8% | -26.8% | -25.1% | 4.7% | -16.1% | -12.9% | -59.7% | |
| SG&A Expense | 80.7% | 17.4% | -6.7% | -24.7% | 11.7% | -11.8% | 67.4% | -16.0% | -14.9% | -4.0% | |
| Total Assets | -34.4% | -36.7% | -43.4% | -37.4% | 41.7% | -20.2% | 18.7% | -68.5% | 1061.0% | -5.3% | |
| Book Value / Share | -34.2% | -54.9% | -48.8% | -75.9% | 162.1% | -76.4% | -77.8% | -108.2% | 4077.4% | -63.8% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -76.9% | |
| Diluted Shares | 38.2% | 5.9% | 23.5% | 18.9% | 72.5% | 35.9% | 45.5% | 56.8% | 144.0% | 252.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.71
10Y Low / Med / High0.01 / 0.05 / 0.33
EV/EBITDAAt Loss
10Y Low / Med / High0.21 / 0.46 / 1.21
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$8.35
Cash / Share
$4.29
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.04 | 0.05 | 0.04 | 0.17 | 0.07 | 0.23 | 0.33 | -1.33 | 0.01 | 0.01 | 0.71 | |
| EV/EBITDA | 1.21 | 0.77 | 0.33 | 0.21 | 0.75 | 0.46 | 0.71 | 0.35 | -0.05 | 0.24 | -0.31 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-12.67
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $9.6M | $0.00 | $0.00 |
| Net Income | -$207.5K | -$115.5K | -$66.1K |
| EPS | $-9.86 | $-5.49 | $-3.14 |
| # Analysts (EPS) | 1 | 1 | 2 |